Agentic AI is emerging as a powerful theme in U.S. healthcare stocks, as investors look for companies that use autonomous AI “agents” to streamline clinical…
Artivion, Inc. (NYSE: AORT) has completed its acquisition of Endospan Ltd., bringing the FDA‑approved NEXUS Aortic Arch System fully in‑house and strengthening its position in complex aortic…
Biogen Inc. (NASDAQ: BIIB) shares jumped 10% Thursday after the company unveiled positive results from its Phase 2 CELIA study of diranersen, an experimental Alzheimer’s…
May 13, 2026
United Therapeutics Corporation Targets Rare Pulmonary Disease via Varda Space Microgravity Platform
United Therapeutics Corporation (NASDAQ: UTHR) officially announced a landmark collaboration with Varda Space Industries on May 13, 2026. This strategic partnership for United Therapeutics aims…
Bayesian Health just secured first-of-its-kind FDA clearance for a continuous, AI-based sepsis monitoring system designed to watch patients in real time across the hospital—not just…
Moderna, Inc. (NASDAQ: MRNA) is back in play after a fresh infectious‑disease scare put a spotlight on its mRNA platform again. Shares jumped about 8%…
Plus Therapeutics’ (NASDAQ: PSTV) diagnostic subsidiary, CNSide, has cleared an important hurdle to unlock U.S. government reimbursement, gaining the regulatory footing needed to enroll in…
Lexaria Bioscience (Nasdaq: LEXX) advanced its next human study toward a mid-June dosing start, with ethics submission filed, manufacturing of test articles complete, and third-party…
Novo Nordisk (NYSE: NVO) is launching an oral version of Ozempic for adults with type 2 diabetes in the U.S. starting May 4, 2026. The…
While headlines stay locked on hyperscaler GPU orders and the megacap AI trade, a smaller story has been quietly building at the intersection of semiconductors,…
April 28, 2026
Quoin Pharmaceuticals Expands QRX009 Platform with Multi-Indication Clinical Roadmap for 2026
Quoin Pharmaceuticals (NASDAQ: QNRX) has outlined a clinical and regulatory roadmap that expands the development path for QRX009, its proprietary topical rapamycin platform. The company…
Adagio Medical (NASDAQ: ADGM) reported positive six‑month results from its pivotal FULCRUM‑VT trial evaluating the vCLAS ventricular ablation system in patients with drug‑refractory ventricular tachycardia (VT)….